Showing results (61-70 of 180) with videos related to

Sort By:
Pageof 18
British Journal of Haematology|July 10, 2018
Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised studyKara-Louise Royle, Walter M Gregory, David A Cairns, et al.
Haematologica|October 8, 2008
Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registryEsa Jantunen, Carmen Canals, Alessandro Rambaldi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2013
Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatmentGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
British Journal of Haematology|November 12, 2025
COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK's Haematological Malignancy Research NetworkAlexandra Smith, Clare Frobisher, Abraham Varghese, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 8, 2021
Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple MyelomaJessica Caro, David Cairns, Tom Menzies, et al.
Trials|October 3, 2020
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitorSamantha Hinsley, Katrina Walker, Debbie Sherratt, et al.
Oncology and Therapy|February 25, 2021
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and RussiaGordon Cook, Alessandro Corso, Matthew Streetly, et al.
Blood|February 4, 2015
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reductionAndy C Rawstron, Walter M Gregory, Ruth M de Tute, et al.
Bone Marrow Transplantation|June 29, 2022
Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory studyJohn A Snowden, Sam H Ahmedzai, Angela Cox, et al.
British Journal of Haematology|July 30, 2015
Time to redefine MyelomaGuy Pratt, Stella Bowcock, Andrew Chantry, et al.
Pageof 18